Analysis of case characteristics of four kinds of antibody-positive patient with myasthenia gravis complicated with rheumatoid arthritis

doi:10.3877/cma.j.issn.2095-655X.2021.01.008

Abstract

Abstract:

Objective

To explore the diagnostic features of four antibody-positive patient with myasthenia gravis (MG) combined with rheumatoid arthritis(RA).

Methods

The clinical data of a MG patient with four antibody-positive combined with RA in the Rheumatology Department of Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine were retrospectively analyzed, and related literatures were reviewed.

Results

The patient was diagnosed with MG and RA with ptosis, fatigue, dysphagia, symmetrical polyarticular swelling and pain four years and six months ago. He was given pyridostigmine bromide, prednisone acetate, methotrexate, leflunomide and hydroxychloroquine, and the above symptoms improved. Due to the discontinuation of pyridostigmine bromide and prednisone acetate reduction, the disease recurred. After perfecting the MG-related antibodies examinations, it was found that the acetylcholine receptor (AChR) antibody, the muscle-specific tyrosine kinase (MuSK) antibody, the ryanodine receptor (RyR) antibody, and the acetylcholinesterase (AChE) antibody were positive at the same time. Adjusting the treatment plans to prednisone acetate, cyclosporine and pyridostigmine bromide, the condition was gradually eased.

Conclusion

Four kinds of antibodies can be detected in patients with MG and RA, suggesting that different antibody-mediated pathogenic mechanisms may exist in autoimmune overlap.

Key words: Myasthenia gravis, Arthritis, rheumatoid, Receptors, cholinergic, Receptor protein-tyrosine kinases, Ryanodine receptor calcium release channel

Zhijuan Sun, Jingfeng Liu, Jingyang Zhang, Hongjun Hao. Analysis of case characteristics of four kinds of antibody-positive patient with myasthenia gravis complicated with rheumatoid arthritis[J]. Chinese Journal of Diagnostics(Electronic Edition), 2021, 09(01): 30-34.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2021.01.008

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2021/V09/I01/30

Figures/Tables 1

References 30

[1]	Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies[J]．Nat Med，2001，7(3):365-368.
[2]	Higuchi O, Hamuro J, Motomura M，et al.Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis[J]．Ann Neurol，2011，69(2):418-422.
[3]	Zhang B, Tzartos JS, Belimezi M，et al.Autoantibodies to lipoprotein related protein 4 in patients with double-seronegative myasthenia gravis[J]．Arch Neurol，2012，69(4):445-451.
[4]	Pevzner A, Schoser B, Peters K，et al.Anti-LRP4 autoantibodies in AChR and MuSK antibody-negative myasthenia gravis[J]．Neurol，2012，259(3):427-435.
[5]	Zhang B, Shen C, Bealmear B, et al. Autoantibodies to agrin in myasthenia gravis patients[J]．PLoS One，2014，9(3):e91816.
[6]	王述进，刘旭峰，黎国红．类风湿性关节炎合并强直性脊柱炎临床诊断特征分析[J/CD]．中华诊断学电子杂志，2015，3(1):52-53.
[7]	Gilhus NE, Skeir GO, Romi F. Myasthenia gravis-autoantibody characteristics and their implications for therapy[J]．Nat Rev Neurol，2016，12(5):259-268.
[8]	Gilhus NE.Autoimmune myasthenia gravis[J]．Expert Rev Neurother，2009，9(3): 351-358.
[9]	Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis：recommendations for clinical research standards.Task force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America[J]．Neurology，2000，55(1):16-23.
[10]	Mao ZF, Yang LX, Mo XA，et al.Frequency of autoimmune diseases in myasthenia gravis: a systematic review[J]．Int J Neurosci，2011，121(3):121-129.
[11]	Gilhus NE, Nacu A, Andersen JB，et al.Myasthenia gravis and risks for comorbidity [J]．Eur J Neurol，2015，22(1):17-23.
[12]	Ragheb S, Lisak R, Lewis R, et al. A potential role for B cell activating factor in the pathogenesis of autoimmune myasthenia gravis[J]．Arch Neurol，2008，65(10):1358-1362.
[13]	Hong YH, Sung JJ. Auto-reactive B cells in MuSK myasthenia gravis[J]．Neuroimmunol Neuroinflammation，2016，3(8):196-197.
[14]	宋敏，丁晓君，岳耀先，等．B细胞活化因子基因多态性与重症肌无力的相关性研究[J]．中华神经内科杂志，2015，48(7):585-590.
[15]	Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune based rheumatic diseases[J]．Arthritis Rheum，2001，44(6):1313-1319.
[16]	Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis：beyond dagnosis [J]．Exp Rev Clin Immunol，2012，8(5):427-438.
[17]	Evoli A, Tonali PA, Padua L，et al.Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis[J]．Brain，2003，126(Pt10):2304-2311.
[18]	Verschuuren JJ, Palace J, Gilhus NE.Clinical aspects of myasthenia explained[J]．Autoimmunity，2010，43(5-6):344-352.
[19]	Ohta K, Shigemoto K, Kubo S, et al. MuSK Ab described in seropositive MG sera found to be Ab to alkaline phosphatase[J]．Neurology，2005，65(12):1988.
[20]	母艳蕾，张华，国红，等．AchR及MuSK双抗体阳性重症肌无力三例并文献复习[J]．中国神经免疫学和神经病学杂志，2018，25(2):80-86.
[21]	Poulas K, Koutsouraki E, Kordas G，et al.Anti-MuSK and anti-AChR-positive myasthenia gravis induced by d-penicilamine[J]．Neuroimmunol，2012，250(1-2):94-98.
[22]	Zouvelou V, Kyriazi S, Rentzos M，et al.Double-seroposifive myasthenia gravis[J]．Muscle Nerve，2013，47(3):465-466.
[23]	Kawakami Y, Ito M, Hirayama M，et al.Anti-MuSK autoantibodies block binding of collagen Q to MuSK[J]．Neurology，2011，77(20):1819-1826.
[24]	Romi F, Hong Y, Gilhus NE.Pathophysiology and immunological profile of myasthenia gravis and its subgroups[J]．Curr Opin Immunol，2017(49):9-13.
[25]	王巍炜，梁芙茹，郝洪军，等．重症肌无力患者血清Ryanodine受体抗体检测及意义[J]．中华神经免疫学和神经病学杂志，2007，14(1):40-42.
[26]	Provenzano C, Marino M, Scuderi F，et al.Anti-acetylcholinesterase antibodies associate with ocular myasthenia favis[J]．J Neuroimmunol，2010，218(1-2):102-106.
[27]	Bryant A, Atkins H, Pringle CE，et al.Myasthenia gravis treated with autologous hematopoietic stem cell transplantation[J]．JAMA Neurol，2016，73(6):652-658.
[28]	Horváth B, Huizinga J, Pas HH，et al.Low-dose rituximab is effective in pemphigus[J]．Br J Dermatol，2012，166(2):405-412.
[29]	Fang F, Sveinsson O, Thormar G，et al.The autoimmune spectrum of myasthenia gravis：a Swedish population-based study[J]．Intern Med，2015，277(5):594-604.
[30]	Eker A, Tnazl M, Mut SE. Coexistence of anti-MuSK antibody-positive myasthenia gravis and rheumatoid arthritis[J]．Egypt J Neurol Psychiatr Neurosurg，2020，56(1):362-368.

Please choose a citation manager

Content to export